Aurobindo Pharma Limited (NSE: AUROPHARMA)
India
· Delayed Price · Currency is INR 1,262.45
+9.50 (0.76%)
Dec 24, 2024, 3:29 PM IST
Aurobindo Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 301,644 | 290,019 | 248,554 | 234,555 | 247,746 | 230,985 | Upgrade
|
| Other Revenue | 1,306 | - | - | - | - | - | Upgrade
|
| Revenue | 302,950 | 290,019 | 248,554 | 234,555 | 247,746 | 230,985 | Upgrade
|
| Revenue Growth (YoY) | 12.41% | 16.68% | 5.97% | -5.32% | 7.26% | 18.07% | Upgrade
|
| Cost of Revenue | 128,772 | 129,857 | 116,417 | 104,499 | 101,898 | 100,286 | Upgrade
|
| Gross Profit | 174,178 | 160,162 | 132,137 | 130,056 | 145,849 | 130,699 | Upgrade
|
| Selling, General & Admin | 43,179 | 40,434 | 36,560 | 35,751 | 36,576 | 33,333 | Upgrade
|
| Other Operating Expenses | 65,855 | 60,894 | 58,083 | 49,976 | 54,183 | 48,298 | Upgrade
|
| Operating Expenses | 124,376 | 116,247 | 107,018 | 96,992 | 101,313 | 91,298 | Upgrade
|
| Operating Income | 49,802 | 43,915 | 25,119 | 33,064 | 44,536 | 39,401 | Upgrade
|
| Interest Expense | -3,671 | -2,681 | -1,290 | -368.4 | -595.7 | -2,870 | Upgrade
|
| Interest & Investment Income | 2,883 | 2,883 | 1,485 | 349.7 | 223.7 | 209.1 | Upgrade
|
| Earnings From Equity Investments | -163.4 | -171.6 | -116.7 | -312.5 | -553.6 | -151.7 | Upgrade
|
| Currency Exchange Gain (Loss) | 464.7 | 387.8 | - | 699.6 | 1,036 | 1,057 | Upgrade
|
| Other Non Operating Income (Expenses) | 2,430 | 1,672 | 974.6 | 1,028 | 1,521 | 153.9 | Upgrade
|
| EBT Excluding Unusual Items | 51,745 | 46,006 | 26,173 | 34,461 | 46,167 | 37,799 | Upgrade
|
| Merger & Restructuring Charges | -289.1 | -986.6 | - | - | - | - | Upgrade
|
| Impairment of Goodwill | -27.4 | -27.4 | -70.3 | - | -4,349 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 1 | 1 | - | 290.8 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 234.9 | 234.9 | 132.3 | -400.2 | -1,411 | -370.4 | Upgrade
|
| Asset Writedown | -2,834 | -2,834 | -239.6 | -1,922 | - | - | Upgrade
|
| Other Unusual Items | 1,407 | 1,407 | 130.1 | 1,298 | 33,029 | 1.9 | Upgrade
|
| Pretax Income | 50,237 | 43,800 | 26,125 | 33,727 | 73,436 | 37,430 | Upgrade
|
| Income Tax Expense | 14,412 | 12,110 | 6,849 | 7,256 | 20,098 | 8,994 | Upgrade
|
| Earnings From Continuing Operations | 35,825 | 31,690 | 19,277 | 26,471 | 53,338 | 28,437 | Upgrade
|
| Minority Interest in Earnings | -8.5 | 40 | -1.5 | 10.4 | 10.2 | 14.5 | Upgrade
|
| Net Income | 35,816 | 31,730 | 19,275 | 26,482 | 53,348 | 28,451 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.1 | Upgrade
|
| Net Income to Common | 35,816 | 31,730 | 19,275 | 26,482 | 53,348 | 28,451 | Upgrade
|
| Net Income Growth | 54.02% | 64.62% | -27.21% | -50.36% | 87.51% | 20.32% | Upgrade
|
| Shares Outstanding (Basic) | 584 | 586 | 586 | 586 | 586 | 586 | Upgrade
|
| Shares Outstanding (Diluted) | 584 | 586 | 586 | 586 | 586 | 586 | Upgrade
|
| Shares Change (YoY) | -0.49% | - | - | - | - | 0.00% | Upgrade
|
| EPS (Basic) | 61.31 | 54.15 | 32.90 | 45.20 | 91.05 | 48.56 | Upgrade
|
| EPS (Diluted) | 61.31 | 54.15 | 32.90 | 45.19 | 91.05 | 48.56 | Upgrade
|
| EPS Growth | 54.79% | 64.62% | -27.21% | -50.37% | 87.51% | 20.31% | Upgrade
|
| Free Cash Flow | -4,952 | -3,458 | -170.5 | 29,636 | 18,911 | 29,985 | Upgrade
|
| Free Cash Flow Per Share | -8.48 | -5.90 | -0.29 | 50.58 | 32.27 | 51.17 | Upgrade
|
| Dividend Per Share | 1.500 | 4.500 | 3.000 | 9.000 | 4.000 | 3.000 | Upgrade
|
| Dividend Growth | - | 50.00% | -66.67% | 125.00% | 33.33% | 20.00% | Upgrade
|
| Gross Margin | 57.49% | 55.22% | 53.16% | 55.45% | 58.87% | 56.58% | Upgrade
|
| Operating Margin | 16.44% | 15.14% | 10.11% | 14.10% | 17.98% | 17.06% | Upgrade
|
| Profit Margin | 11.82% | 10.94% | 7.75% | 11.29% | 21.53% | 12.32% | Upgrade
|
| Free Cash Flow Margin | -1.63% | -1.19% | -0.07% | 12.63% | 7.63% | 12.98% | Upgrade
|
| EBITDA | 63,952 | 57,641 | 36,344 | 43,114 | 53,947 | 48,017 | Upgrade
|
| EBITDA Margin | 21.11% | 19.87% | 14.62% | 18.38% | 21.78% | 20.79% | Upgrade
|
| D&A For EBITDA | 14,150 | 13,726 | 11,225 | 10,050 | 9,411 | 8,617 | Upgrade
|
| EBIT | 49,802 | 43,915 | 25,119 | 33,064 | 44,536 | 39,401 | Upgrade
|
| EBIT Margin | 16.44% | 15.14% | 10.11% | 14.10% | 17.98% | 17.06% | Upgrade
|
| Effective Tax Rate | 28.69% | 27.65% | 26.21% | 21.51% | 27.37% | 24.03% | Upgrade
|
| Revenue as Reported | 309,358 | 295,593 | 251,460 | 237,758 | 251,555 | 232,904 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.